ul. gen. Mariana Langiewicza 60
Konstantynów Lódzki 95-050
Poland
48 42 207 7890
https://www.mabion.eu
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 241
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Krzysztof Kaczmarczyk | CEO & President of Management Board | S.O. | S.O. | S.O. |
Mr. Grzegorz Grabowicz | CFO & Member of Management Board | S.O. | S.O. | 1973 |
Dr. Slawomir Jaros EMBA, Eng., Ph.D. | Chief Operating & Scientific Officer and Member of the Management Board | S.O. | S.O. | S.O. |
Mr. Adam Pietruszkiewicz | Chief Sales Officer & Member of Management Board | S.O. | S.O. | S.O. |
Aneta Turek | Chief Accountant | S.O. | S.O. | S.O. |
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland.
L’ISS Governance QualityScore de Mabion S.A. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..